Introduction
Cholangiocarcinoma (CCA) is the most common biliary malignancy and the second most common primary hepatic malignancy after hepatocellular carcinoma (HCC). CCAs are heterogeneous biliary epithelial tumours that are classified into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes based on their anatomic location within the biliary tree. The overall incidence of CCA, particularly iCCA, has increased over recent decades. Unfortunately, the 5-year overall survival (OS) for CCA remains less than 10%.
1,2 Surgical resection or liver transplantation following neoadjuvant chemoradiation are potentially curative treatment options for the subset of patients who present with early-stage disease. 2 However, diagnosing CCA at an early stage remains a significant challenge, and the majority of patients present with advanced stage disease. [2] [3] [4] [5] Advances in our understanding of the immunobiology of the tumour immune microenvironment (TIME) have resulted in the advent of cancer immunotherapies that modulate the host immune response against tumours. 6 Tumours can escape the host immune attack by induction of immune checkpoints such as programmed death-1 (PD-1) and its ligand PD-L1, as well as cytotoxic T-lymphocyte-associated protein 4
(CTLA-4). Accordingly, antibody-based therapies targeting these mediators, so called immune checkpoint blockade (ICB), unleash pre-existing immunity and have become the major focus of anticancer therapeutic interventions. ICB therapies have demonstrated durable responses in a subset of patients. 7 ICB response is associated with the TIME phenotype, with a T cellinfiltrated TIME having a higher response to ICB compared to a non-T cell infiltrated TIME. 6, 8 A T cell-infiltrated TIME displays spontaneous immune activation and is characterized by the presence of high infiltration of CD8 + T cells, high expression of PD-L1, chemokines and other factors implicated in T cell recruitment. A non-T cell infiltrated TIME displays immune exclusion and lacks T cells due to the absence of chemokines and activation factors involved in T cell recruitment. 6, 8 The latter phenotype also lacks T cell priming, likely due to the absence of upstream innate immune activation. CCAs are desmoplastic tumours with a dense TIME populated by cancer-associated fibroblasts as well as immunosuppressive innate immune cells such as tumour-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). These stromal elements are essential in promoting an immunosuppressive TIME and foster CCA progression by producting cytokines and chemokines. Herein, we review the innate and adaptive host immune response to CCA and emerging immunotherapies modulating the immune system. 9 The innate immune system in cholangiocarcinoma
The liver has ample unique immunological features including the ability to induce immune tolerance as well as a robust innate immunity. 10 The liver is constantly exposed to intestinal microbial products and must have the ability to suppress inappropriate inflammatory responses while remaining alert to potential harmful stimuli such as infectious agents or cancer cells. 10 The liver's distinct immune environment includes the largest population of resident macrophages (80-90% of total body population) referred to as Kupffer cells (KCs) and an abundance of natural killer (NK) cells. 10, 11 KCs are key mediators of induction of immunological tolerance in the liver. The tolerogenic capability of the liver may be important in tumour biology as cancers may co-opt this machinery to promote immune tolerance, facilitating tumour progression. Hence, elucidating the innate immune response to CCA is essential in the effort to uncover effective immunotherapies. 12 
Macrophages in cholangiocarcinoma
Macrophages are phagocytic innate immune cells which are extremely heterogeneous, and play an essential role in hepatobiliary malignancy. 11, 13 They represent the first line of defence against damage-associated molecular patterns expressed by cancer cells, or pathogen-associated molecular patterns. 14 Hepatic macrophages may be categorized by ontogeny as resident or recruited macrophages. Resident macrophages include yolk-sac derived KCs which have the capacity to selfrenew, and a recently described population of liver capsular macrophages which are replenished from blood monocytes. 15 Recruited hepatic macrophages include circulating monocytes that differentiate into macrophages, and a reservoir of peritoneal macrophages which traffic through the capsule into the liver parenchyma. 11, 16 Polarization refers to the functional activation of macrophages. In tumour biology, TAMs are an essential component of the TIME, and are implicated in tumour immune escape. 17, 18 The terminology for TAM polarization is complex, and includes an immunosuppressive, alternatively activated, protumour 'M2-like' phenotype and an antitumour, classically activated 'M1-like' phenotype. 18 TIME factors contributing to TAM plasticity include cytokines, as well as hypoxia and cancer cell-derived extracellular vesicles (EVs). [20] [21] [22] [23] 17, 19 Several studies have demonstrated an association between the presence of TAMs and patient outcomes in CCA. 24 In a cohort of 39 patients with iCCA, TAM infiltration was associated with angiogenesis, increased infiltration of regulatory T cells (Treg), and poor disease-free survival. 24 The authors also demonstrated that CCA cells induce an M2-like phenotype via signal transducer and activator of transcription 3 activation. 17, 24 Similarly, a retrospective analysis employing immunohistochemistry (IHC) in 114 patients with CCA demonstrated a positive correlation between tumour-infiltrating neutrophils, TAMs, and Tregs. 25 Moreover, the presence of these immunosuppressive immune cell populations was significantly associated with poor recurrence-free survival. 25 Conflicting results have been obtained from studies assessing a link between TAM localization within the tumour and patient outcomes; one study demonstrated worse outcomes (47 patients with pCCA) and another demonstrated improved OS (88 patients with iCCA) with high infiltration of TAMs in the tumour invasive front. [26] [27] [28] [29] [30] Studies investigating the mechanism of TAMmediated CCA progression are limited. Yuan et al. have demonstrated that chronic liver injury induces mitochondrial dysfunction, resulting in oxidative stress and the recruitment of KCs. 31 Moreover, tumor necrosis factor (TNF) derived from KCs promotes JNK-mediated CCA proliferation and oncogenic transformation, depletion of KCs has been shown to reduce pre-malignant CCA lesions. 31 Canonical WNT signalling drives cell proliferation, and is activated in CCA. 32 Alternatively activated macrophages activate WNT signalling in CCA with consequent CCA progression. 32 Macrophage depletion in preclinical models results in inhibition of WNT signalling, and reduction in tumour growth. 32 As TAM infiltration has been associated with poor patient outcomes, it has been postulated that CCA cells may modulate the surrounding stroma to a tumour supportive immune niche. Cellular spheroids
Key points
Infiltration of immunosuppressive innate immune cells such as TAMs and MDSCs in CCA is associated with poor patient outcomes.
T cell-infiltrated or immune 'hot' CCAs have increased CD8+ T cell infiltration with enhanced interferon γ and granzyme B activity, increased expression of immune checkpoint molecules such as PD-1 and its ligand PD-L1, and enhanced responsiveness to ICB.
Non-T cell-infiltrated or immune 'cold' CCAs are devoid of CD8+ T cells and have a preponderance of immunosuppressive cells such as TAMs, MDSCs, and tolerogenic DCs.
Conventional chemotherapy has limited efficacy in metastatic cholangiocarcinoma, prompting interest in immunotherapy approaches. The only FDA-approved immunotherapy in cholangiocarcinoma is pembrolizumab, an anti-PD-1 antibody, which received tissue-agnostic approval for solid tumours with microsatellite instability or mismatch repair deficiency, including cholangiocarcinoma.
The response rate to PD-1 blockade monotherapy is low in unselected cases of advanced cholangiocarcinoma, underscoring the need for biomarkers of response, novel immunotherapies, and combination therapies.
Immune-mediated approaches currently under investigation include combining immune checkpoint blockade with molecularly targeted therapy, local ablative therapy, chemotherapy, and other agents. Cell-based therapies, cancer vaccines, and agents targeting novel immune checkpoints, cytokines, colony stimulating factors, and the tumour microenvironment are also under development.
generated from CCA cells molded macrophages to a TAM phenotype with high invasive capacity. 33 TAMs isolated from resected human CCA specimens recapitulated the phenotype of the in vitro macrophages educated by CCA cells. 33 Although these studies have explored the mechanisms underlying TAM-mediated CCA progression, further work is needed to elucidate the mechanisms behind the pro-tumour role of macrophages in CCA. 40 The majority of data regarding the role of MDSCs in hepatobiliary cancers come from HCC. Clinically, an increase in M-MDSC in peripheral blood is prognostic, and has been associated with decreased OS in HCC. 41 In murine models of 51, 52 Natural killer group 2D (NKG2D), an activating NK cell receptor, is involved in NK cell-mediated killing of tumour cells. Genetic variants of the NKG2D receptor impair the cytotoxic function of NK cells. Accordingly, NKG2D receptor variants have been linked to CCA development in patients with primary sclerosing cholangitis. 53 In contrast, high expression of NKG2D ligands in human CCA are associated with improved disease-free and overall patient survival, implying that treatment strategies that encourage interaction between NKG2D and its ligand may be a promising therapeutic approach in CCA. 54 Preclinical data from studies assessing therapeutic strategies that augment NK cell activity in CCA are encouraging, albeit limited. Co-culture of CCA cells with the epidermal growth factor receptor monoclonal antibody, cetuximab, and NK cells significantly enhanced CCA cell death by potentiating antibodydependent cellular cytotoxicity. 55 Similarly, infusion of ex vivo expanded human NK cells into CCA xenograft mice resulted in inhibition of tumour growth. 56 Although these findings hold promise, further work is needed to investigate NK cellbased therapies in CCA. Compared to healthy controls, patients with CCA have a significant decrease in the absolute number of peripheral blood cDCs as well as a decline in the TNFα-producing cDCs. 60 Immunohistochemical analysis has demonstrated a correlation between CD83 + (mature) cDCs and CD4 + /CD8 + T cell infiltration at the invasive margin of cancer. Moreover, patients with an increased number of CD83 + cDCs at the tumour invasive margin had a lower incidence of lymph node metastasis and overall better outcomes compared to patients with a paucity of CD83 + cDCs. 61 As the presence of DCs confers a better patient outcome, the therapeutic potential of DC-based immunotherapies has been explored in limited preclinical and clinical studies of CCA. DCs loaded with aspartate-β-hydroxylase (ASPH), a tumourassociated cell surface protein present in a number of malignancies, induced suppression of tumour growth and metastasis, as well as increased CD3 + lymphocyte infiltration in an orthotopic rat model of iCCA. 62 Interestingly, the remaining tumour cells still expressed ASPH. This latter finding implies that "escape mutants" mediating tumour evasion had not developed, and additional immunizations may be necessary for optimal antitumour activity. 62 Overall, the role of DCs and various DC subsets in CCA needs to be further delineated. 70, 78 rather than cancer cells (9-23%).
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Dendritic cells in cholangiocarcinoma
Adaptive immune response in cholangiocarcinoma
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High PD-L1 expression has been linked to an increase in apoptotic TILs. 80 FoxP3 + TILs have also been implicated in CD8 + T cell apoptosis and consequent tumour immune escape in CCA. 81 Indeed, downregulation of FoxP3 results in the attenuation of CCA proliferation and invasion, as well as enhanced tumour cell apoptosis. 81 Although CD20 + B cells represent a minor proportion of the total TIL population in CCA, their presence has been linked to a favourable prognosis in CCA. 66, 72 Collectively, our knowledge of the adaptive immune system in CCA is based primarily on small retrospective studies utilizing immunohistochemical analysis. Future studies should employ sophisticated immunoprofiling techniques such as mass cytometry to elucidate the role of the adaptive immune system in CCA.
Immunotherapy clinical trials in cholangiocarcinoma Standard of care
The standard first-line treatment for advanced biliary tract cancers (BTCs), including cholangiocarcinoma, is gemcitabine and cisplatin combination chemotherapy. This regimen modestly increased survival, with a median OS of 11.7 months in patients treated with gemcitabine/cisplatin, compared to 8.1 months for those treated with gemcitabine alone in a phase III trial. 82 The use of other gemcitabine or fluoropyrimidinebased chemotherapy regimens is supported by phase II trials. An open-label, single-arm, phase II clinical trial demonstrated prolonged median progression free survival (PFS) (11.8 months) and median OS (19.2 months) in patients with advanced BTC (n = 62) treated with nab-paclitaxel plus gemcitabine-cisplatin compared to historical controls treated with gemcitabine-cisplatin alone. 83 However, given the limited efficacy of these regimens, there is a pressing need to develop additional therapeutic approaches.
Immune checkpoint blockade
Immune checkpoint inhibitors are designed to overcome inhibitory receptors on CTLs to promote an antitumour immune response. Agents targeting the PD-1 and CTLA-4 pathways have been approved in multiple malignancies, and in some cases provide durable responses. However, even among immunogenically 'hot' tumour types such as melanoma and non-small cell lung cancer, response to ICB is variable. Current research priorities in CCA and other tumour types include determining biomarkers of response, and developing combination strategies to improve response rates and circumvent immunologic tolerance and resistance. 84 One established predictor of response to ICB is the neo-antigen burden of a tumour, which may be secondary to carcinogen exposure, oncoviral integration, APOBEC gene expression, microsatellite instability due to mismatch repair deficiency (MSI-high/MMR-deficient), or other factors. In a comprehensive molecular analysis, approximately 6% of biliary cancers were hypermutated (with a tumour mutation rate >11.13/Mb), including 2% that were MMRdeficient. 85 This suggests that a subset of CCAs may be primed to respond to ICB (Fig. 2) . Indeed, ICB has shown promise in patients with MSI-high/ MMR-deficient CCA. The efficacy of pembrolizumab, a monoclonal anti-PD-1 antibody, was evaluated in a prospective manner in 86 patients with advanced MSI-high/MMR-deficient cancers including CCA (n = 4). 86 The disease control rate (DCR) in patients with CCA was 100%; 1 patient had complete response (CR) and 3 had stable disease. 86 , including 1 CR and 3 PR; an additional 3 patients had stable disease. Median PFS was 1.8 months, and median OS was 6.2 months. Multiple biomarkers were evaluated, including expression of an 18-gene T cell-inflamed profile, PD-L1 expression, and tumour mutational burden (TMB). All 3 were correlated with higher response rates in the study population overall, and the highest response rates were found among patients with both elevated TMB and a second biomarker (PD-L1 expression or T cell-inflamed gene expression profile). 77 Although biomarker data was not presented for the biliary cancer cohort specifically, these results suggest that a combination of biomarkers can identify patients most likely to respond to ICB. These encouraging results led to a follow-up trial with an expansion cohort, KEYNOTE-158 (NCT02628067), the largest study to date of ICB in BTCs. This is an ongoing phase II, single-arm, open-label trial of pembrolizumab in multiple advanced cancers. An interim report was presented in 2018 with data from 104 patients with BTC. 88 The ORR was only 5.8%, including 6 PR and zero CR, with an additional 17 patients (16%) having stable disease. The duration of response (DoR) ranged from 6.2 to >15 months (in 2 patients), with the median DoR not reached. Interestingly, PD-L1 expression was not predictive of response. The cohort contained 61 patients with PD-L1 positive tumours, and 31 patients without PD-L1 expression. Although ORR was slightly higher in the PDL-1 positive group (6.6% vs. 2.9%), there were no significant differences in median PFS (1.9 vs. 2.1 months) or OS (7.2 vs. 9.6 months). 88 In this cohort, none of the evaluated patients had MSI-high tumours. This limited response to ICB monotherapy in an unselected cohort of advanced biliary cancer further emphasizes the need for biomarkers (that identify patients likely to respond), and combinatorial treatment strategies (that overcome limited antitumour responses in CCA).
Immune checkpoint blockade -combination therapies Given the limitations of ICB monotherapy, there is tremendous interest in developing combination immunotherapy strategies. Such strategies include dual ICB as well as ICB combined with another immunomodulatory agent, molecular targeted therapy, cytotoxic chemotherapy, or local therapy (Tables 1 and 2 ). 89 The premise of dual ICB is that blocking a single checkpoint may not be sufficient to activate CTLs. Although combining CTLA-4 and PD-1 blockade has increased efficacy, it has also increased adverse events (AE) in melanoma. Beyond CTLA-4 and PD-1, there are a host of additional immune checkpoints which may be modulated to promote an antitumour immune response, including the inhibitory receptors LAG-3, TIM-3, TIGIT, and VISTA, and activating receptors OX40, GITR, 4-1BB, and CD40 ligand. 89 Preclinical and clinical data regarding these checkpoints are far less mature, but there is early data from melanoma and renal cell carcinoma suggesting some clinical effect of LAG-3 inhibitors. 93, 94 Clinical trials are currently underway targeting CD40 (NCT03329950) and OX40 (NCT03071757) as single agent or combination therapies in advanced cancers including CCA.
Several cytokine-targeted therapies have been combined with ICB. Granulocyte-macrophage colony-stimulating factor (GM-CSF), encoded by the CSF2 gene, is a cytokine that can increase antigen presentation and cytotoxic T cell function. Systemic administration of GM-CSF in combination with ICB prolonged OS compared to ICB alone in a phase II trial in melanoma. 95 Interim analysis of an open-label, single-arm, phase II trial of pembrolizumab plus GM-CSF in CCA (n = 27; 70% iCCA) showed an ORR of 21% (5 of 24 patients), including PR in 4 patients with microsatellite stable (MSS) tumours. Two additional MSS patients had durable declines in CA19-9 for >11 months.
96
Interferon-alpha-2 is a cytokine that increases antigen presentation via upregulation of host MHC class I and II molecules, leading to increased tumour infiltration of dendritic and T cells. 97 Systemic administration of pegylated interferonalpha-2b is approved for use in the adjuvant setting for treatment of melanoma. 98 In CCA, clinical trials evaluating interferon-alpha-2 with pembrolizumab (NCT02982720) or in combination with chemotherapy (NCT00019474) are currently ongoing. Other ongoing trials in CCA featuring immunomodulators include a fusion protein designed to inhibit PD-L1 and TGF-β, an immunosuppressive cytokine (NCT03825705), 99 and recombinant IL-12, a pro-inflammatory cytokine, combined with HER2 targeted therapy (NCT00004074; 
NCT03872947
Ongoing clinical trials were identified by searching ClinicalTrials.gov using the terms "Biliary Cancer," "cholangiocarcinoma," "biliary carcinoma," "bile duct," or "biliary tract" and manually curated for inclusion of an immunotherapy arm. Trials were included with status of "Recruiting," "Not yet recruiting," "Active, not recruiting," "Completed," or "Enrolling by invitation." Trials of general solid tumours were excluded unless a BTC arm or inclusion was specified. Search was updated as of 4/1/19. BTC, biliary tract cancer; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; ICB, immune checkpoint blockade; MMR, mismatch repair; PDAC, pancreatic ductal adenocarcinoma; RFA, radio frequency ablation; SBRT, Stereotactic body radiation therapy; TACE, transarterial chemoembolization; TMB, tumor mutational burden.
patients with biliary cancer (42% iCCA). 102 Of 24 evaluable patients, only 1 patient had PR (4%) while an additional 9 patients had stable disease, and no patients had CR. Median PFS was 1.6 months, and median OS 6.4 months. Overall, there was no response to this combination compared to historical controls. Of note, PD-L1 positive patients had no change in PFS, but had improved OS compared to patients with PD-L1 negative disease (11.3 vs. 6.1 months). Although these data support PD-L1 as a biomarker for ICB response, the small sample size and the lack of significant difference in outcomes in PD-L1 positive patients reported for KEYNOTE-158 suggests that further studies are necessary. At least 3 additional ongoing trials are evaluating the combination of VEGFR blockade and ICB (Table 2) . CCAs are characterized by a desmoplastic stroma with dense extracellular matrix (ECM). Hyaluronidase is an enzyme that breaks down hyaluronic acid in the ECM. In pancreatic cancer, which is similarly desmoplastic, an interim analysis of a phase II trial showed that PEGylated recombinant human hyaluronidase (PEGPH20) increased ORR and PFS. 103 This agent is now being evaluated in combination with ICB and chemotherapy in CCA (NCT03267940).
Combination of immune checkpoint blockade and molecular targeted therapy
Integrative genomic analysis of BTCs has identified recurrent genetic alterations which may be amenable to targeted therapy. 104 A tantalizing rationale for combining targeted therapies and immunotherapies is that molecular targeted therapies can produce significant but often short-lived responses in susceptible tumours, which could theoretically be prolonged with Ongoing clinical trials were identified by searching ClinicalTrials.gov using the terms "Biliary Cancer," "cholangiocarcinoma," "biliary carcinoma," "bile duct," or "biliary tract" and manually curated for inclusion of an immunotherapy arm. Trials were included with status of "Recruiting," "Not yet recruiting," "Active, not recruiting," "Completed," or "Enrolling by invitation." Trials of general solid tumours were excluded unless a BTC arm or inclusion was specified. 117 and is currently being evaluated in combination with chemotherapy (FOLFOX, gemcitabine/cisplatin, or paclitaxel) in a phase I/II study of advanced solid tumours including CCA (NCT03314935).
Adoptive cell therapy
As the response to ICB in CCA has been subpar, it is possible that these are immunologically "cold" tumours that lack a substantial tumour-reactive T cell population. Adoptive cell therapy using CTLs or NK cells attempts to overcome this limitation (Fig. 3) (Table 3) .
Other immunotherapeutic strategies
Other immunotherapeutic strategies of interest in CCA include peptide or DC-based vaccines, oncolytic viruses, and attenuated bacteria-based therapies. Peptide and DC-based vaccines are designed to increase antigen presentation and T cell priming in immunologically "cold" tumours, while viral and bacterial vectors simultaneously lyse tumour cells, increase antigen presentation, and stimulate a T cell response (Fig. 3) 
Future perspectives
The prevailing knowledge on the immunobiology of CCA is based primarily on IHC analyses. monotherapy in CCA, effective combination immunotherapeutic strategies which harness the innate as well as the adaptive immune response to CCA are required (Figs. 2 and 3 ). Such strategies would couple ICB with immunotherapies targeting immunosuppressive immune cells in CCA. Consequently, a greater understanding of the immunobiology of CCA will direct development of combination immunotherapeutic strategies. Although a T cell-inflamed TIME, high TMB, and even PD-L1 expression may correlate with response in other tumour types, the utility of these biomarkers in CCA is unknown. Accordingly, investigative efforts should also be directed towards development of biomarkers which predict response to immunotherapy in CCA.
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